Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma
Year: 2025
Type: article
Source: eJHaem
DOI: 10.1002/jha2.70182
Author: Raza Ur Rehman
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,860
OpenAlex ID: W4416411342